

References

1. Alderman M, Redfern JS. Serum uric acid – a cardiovascular risk factor? *Ther Umsch* 2004;61(9):547–52.
2. Alimonda AL, Núñez J, Núñez E, Husser O, Sanchis J, Bodí V, Miñana G, Robles R, Mainar L, Merlos P, Darmofal H, Llácer A. Hyperuricemia in acute heart failure. More than a simple spectator? *Eur. J. Intern. Med* 2009;20(1):74–9.
3. Angermann CE, Gelbrich G, Störk S, Schowalter M, Deckert J, Ertl G, Faller H. Competence Network Heart Failure. Somatic correlates of comorbid major depression in patients with systolic heart failure. *Int J Cardiol* 2011;147(1):66–73.
4. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. *Circulation* 2003;107(15):1991–7.
5. Bauer JA, Moffatt-Bruce SD, Elton TS, Feldman D. Purine metabolism in heart failure: oxidant biology and therapeutic indications. *Congest Heart Fail* 2008;14(5):283–4.
6. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. *Eur J Heart Fail* 2009;11(5):444–52.
7. Bhandari S. Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. *Front Biosci* 2011;16:1364–87.
8. Bonet LA. Predictors of mortality following heart transplantation: Spanish Registry of Heart Transplantation 1984–2001. *Transplant Proc* 2003;35(5):1946–50.
9. Bowker P. The significance of asymptomatic hyperuricaemia. *N Z Med J* 2002;115(1163):U211.
10. Caldeira J, Belle V, Asso M, Guigliarelli B, Moura I, Moura JGG, Bertrand P. Analysis of the electron paramagnetic resonance properties of the [2Fe-2S]¹⁺ centers in molybdenum enzymes of the xanthine oxidase family: assignment of signals I and II. *Biochemistry* 2000;39:2700–2707.
11. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. *Arthritis Rheum* 2009;61(2):225–232.
12. Corry DB, Tuck ML. Uric acid and the vasculature. *Curr Hypertens Rep* 2006;8(2):116–119.
13. De Angelis S, Noce A, Di Renzo L, Cianci R, Naticchia A, Giarrizzo GF, Giordano F, Tozzo C, Splendiani G, De Lorenzo A. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. *Eur Rev Med Pharmacol Sci* 2007;11(3):179–184.
14. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. *Diabetol Metab Syndr* 2012;4:12.

15. Desai RV, Ahmed MI, Fonarow GC, Filippatos GS, White M, Aban IB, Aronow WS, Ahmed A. Effect of serum insulin on the association between hyperuricemia and incident heart failure. *Am J Cardiol* 2010;106(8):1134–1138.
16. Doehner W, Anker SD. Uric acid in chronic heart failure. *Semin Nephrol* 2005;25(1):61–66.
17. Doehner W, Springer J, Landmesser U, Struthers AD, Anker SD. Uric acid in chronic heart failure – current pathophysiological concepts. *Eur J Heart Fail* 2008;10(12):1269–1270.
18. Doehner W, von Haehling S, Anker SD. Uric acid as a prognostic marker in acute heart failure – new expectations from an old molecule. *Eur J Heart Fail* 2007;9(5):437–439.
19. Duan X, Ling F. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? *Med Hypotheses* 2008;70(3):578–581.
20. Dunkelgrun M, Welten GM, Goei D, Winkel TA, Schouten O, van Domburg RT, van Gestel YR, Flu WJ, Hoeks SE, Bax JJ, Poldermans D. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery. *Am J Cardiol* 2008;102(7):797–801.
21. Edwards NL. The role of hyperuricemia in vascular disorders. *Curr Opin Rheumatol* 2009;21(2):132–137.
22. Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, Filippatos G, Anker SD, Lloyd-Jones DM, Bakris G, Mujib M, Ahmed A. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. *Int J Cardiol* 2010 Jul 23;142(3):279–287.
23. Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF. Crystal structure of bovine milk xanthine dehydrogenase and xanthine oxidase: structure based mechanism of conversion. *Proc Natl Acad Sci USA* 2000;97:10723–10728.
24. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. *Circ Res* 2000;87:241–247.
25. Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. *Eur Heart J* 2011;32(6):712–720.
26. George J. Letter by George regarding article, "Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study". *Circ Heart Fail* 2010;3(3):e10.
27. Godber BL, Doel JJ, Goult TA, Eisenthal R, Harrison R. Suicide inactivation of xanthine oxidoreductase during reduction of inorganic nitrite to nitric oxide. *Biochem J* 2001;358:325–333.
28. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H. for the JCARE-CARD Investigators. Hyperuricemia predicts adverse outcomes in patients with heart failure. *Int J Cardiol* 2010 Jun 12. [Epub ahead of print].

29. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. *Hypertension* 2006;47(2):195–202.
30. Jankowska EA, Ponikowska B, Majda J, Zymliński R, Trzaska M, Reczuch K, Borodulin-Nadzieja L, Banasiak W, Ponikowski P. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. *Int J Cardiol* 2007;115(2):151–155.
31. Kittleson MM, Bead V, Fradley M, St John ME, Champion HC, Kasper EK, Russell SD, Wittstein IS, Hare JM. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. *J Heart Lung Transplant* 2007;26(5):498–503.
32. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M, Tei C, Hiraoka H, Sonoda M, Tsuchihashi K, Shimoyama N, Honda T, Ogata Y, Matsui K, Ogawa H. Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). *Am J Cardiol* 2005;96(4):489–495.
33. Krishnan E. Hyperuricemia and incident heart failure. *Circ Heart Fail* 2009;2(6):556–562.
34. Lee BE, Toledo AH, Anaya-Prado R, Roach RR, Toledo-Pereyra LH. Allopurinol, xanthine oxidase, and cardiac ischemia. *J Investig Med* 2009;57(8):902–909.
35. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. *Clin Chim Acta* 2008;392(1–2):1–7
36. Martínez A, González A, Cerda C, Pérez P, Castro P, Pérez O, Isa R, Corbalán R. Prognostic value of hyperuricemia in chronic heart failure. *Rev Med Chil* 2004;132(9):1031–1036.
37. Moro J, Almenar L, Martínez-Dolz L, Izquierdo M, Agüero J, Sánchez-Lazaro I, Ortiz V, Salvador A. Ezetimibe in heart transplantation: initial experience. *Transplant Proc* 2007;39(7):2389–2392.
38. Niizeki T, Takeishi Y, Arimoto T, Okuyama H, Nozaki N, Hirono O, Tsunoda Y, Watanabe T, Nitobe J, Miyashita T, Takahashi H, Koyama Y, Kubota I. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. *J Cardiol* 2006;47(5):219–228.
39. Ochiai ME, Barretto AC, Oliveira MT Jr, Munhoz RT, Morgado PC, Ramires JA. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. *Eur J Heart Fail* 2005;7(4):468–474.
40. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. *Circ Heart Fail* 2010;3(1):73–81.
41. Oh J, Won HY, Kang SM. Uric acid and cardiovascular risk. *N Engl J Med* 2009;360(5):539–540.
42. Olivero JJ, Nguyen PT, Olivero JJ. Chronic kidney disease: a marker of cardiovascular disease. *Methodist Debaquey Cardiovasc J* 2009;5(2):24–29.

43. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. *Pharmacol Rev* 2006;58(1):87–114.
44. Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. *Eur J Heart Fail* 2007;9(5):518–524.
45. Pinelli M, Bindi M, Filardo FP, Moroni F, Castiglioni M. Serum uric acid levels correlate with left ventricular ejection fraction and systolic pulmonary artery pressure in patients with heart failure. *Recenti Prog Med* 2007;98(12):619–623.
46. Pinelli M, Bindi M, Moroni F, Castiglioni M. Relationship between serum uric acid levels and urinary albumin excretion in patients with heart failure. *Acta. Cardiol* 2008;63(2):191–195.
47. Pitt RM, McKelvey TG, Saenger JS, Shah AK, Jones HP, Mancini EA, Powell RW. A tungsten-supplemented diet delivered by transplacental and breast-feeding routes lowers intestinal xanthine oxidase activity and affords cytoprotection in ischemia-reperfusion injury to the small intestine. *J Pediatr Surg* 1991;26:930–935.
48. Puett DW, Forman MB, Cates CU, Wilson BH, Hande KR, Friesinger GC, Virmani R. Oxypurinol limits myocardial stunning but does not reduce infarct size after reperfusion. *Circulation* 1987;76:678–686.
49. Rashid MA, William-Olsson G. Influence of allopurinol on cardiac complications in open heart operations. *Ann Thorac Surg* 1991;52:127–130.
50. Reimer KA, Jennings RB. Failure of the xanthine oxidase inhibitor allopurinol to limit infarct size after ischemia and reperfusion in dogs. *Circulation* 1985;71:1069–1075.
51. Rondinini L, Coceani M, Borelli G, Guideri S, Chini C, Frediani MR, Maccari M, Mariotti R. Survival and hospitalization in a nurse-led domiciliary intervention for elderly heart failure patients. *J Cardiovasc Med (Hagerstown)* 2008;9(5):470–475.
52. Shadid M, Van Bel F, Steendijk P, Dorrepaal CA, Moison R, Van der Velde ET, Baan J. Pretreatment with allopurinol in cardiac hypoxic-ischemic reperfusion injury in newborn lambs exerts its beneficial effect through afterload reduction. *Basic Res Cardiol* 1999;94:23–30.
53. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? *Nutr Metab Cardiovasc Dis* 2007;17(6):409–414.
54. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. *Circ Res* 2004;95:1005–1011.
55. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. *Hypertension* 2005;45(1):28–33.
56. Terada LS, Radisavljevic Z, Mahr NN, Jacobson ED. Xanthine oxidase decreases production of gut wall nitric oxide. *Proc Soc Exp Biol Med* 1997;216:410–413.

57. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. *Arch Intern Med* 2010;170(15):1358–1364.
58. Wasserman A, Shnell M, Boursi B, Guzner-Gur H. Prognostic significance of serum uric acid in patients admitted to the Department of Medicine. *Am J Med Sci* 2010;339(1):15–21.
59. Wilkins EG, Rees RS, Smith D, Cashmer B, Punch J, Till GO, Smith DJ Jr. Identification of xanthine oxidase activity following reperfusion in human tissue. *Ann Plast Surg* 1993;31:60–65.
60. Wu AH, Ghali JK, Neuberg GW, O'Connor CM, Carson PE, Levy WC. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. *Am Heart J* 2010;160(5):928–933.
61. Yamamoto Y, Matsubara K, Igawa G, Kaetsu Y, Sugihara S, Matsuura T, Ando F, Sonoyama K, Hamada T, Ogino K, Igawa O, Shigemasa C, Hisatome I. Status of uric acid management in hypertensive subjects. *Hypertens Res* 2007;30(6):549–554.
62. Zhang YH, Lü R, Zhao XY, Kang LM, Yang YJ, Zhang J. Association of serum uric acid, plasma NT-proBNP, Hs-C reactive protein and invasive hemodynamic parameters in patients with heart failure. *Zhonghua Xin Xue Guan Bing Za Zhi* 2009;37(2):126–129.